New Zealand markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1,039.11-6.26 (-0.60%)
At close: 04:00PM EDT
1,042.51 +3.40 (+0.33%)
Pre-market: 04:23AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1,045.37
Open1,046.50
Bid0.00 x 0
Ask0.00 x 0
Day's range1,036.00 - 1,052.34
52-week range684.81 - 1,052.34
Volume371,990
Avg. volume425,738
Market cap114.495B
Beta (5Y monthly)0.12
PE ratio (TTM)30.68
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

    At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

  • GlobeNewswire

    Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)

    Approval in patients with pJIA weighing 63kg or greater adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica TARRYTOWN, N.Y. and CAMBRIDGE, MA, June 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for the treatment of patients weighing 63 kg or greater with activ

  • GlobeNewswire

    Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

    Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announ